Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies

• Published in: Cancers Vol. 15; no. 13; p. 3312
• Main Authors: Lo, Justin H, Agarwal, Rajiv, Goff, Laura W, Heumann, Thatcher R
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.06.2023; MDPI
• Subjects: Adenocarcinoma; Agonists; Angiogenesis; Antigens; Antimitotic agents; Antineoplastic agents; B cells; Bile ducts; Biliary tract; Biliary tract diseases; Blood vessels; Cancer; Cancer therapies; Cancer vaccines; Chemotherapy; Cholangiocarcinoma; Cisplatin; Cytotoxicity; Dendritic cells; Drug therapy; ErbB-2 protein; FDA approval; Fibroblast growth factor receptor 2; Fibroblasts; Gallbladder cancer; Gemcitabine; Genotype & phenotype; Immune system; Immunomodulation; Immunostimulation; Immunosuppressive agents; Immunotherapy; Lymphocytes; Lymphocytes T; MAP kinase; Metastases; Oncology, Experimental; Pembrolizumab; Respiratory agents; Review; Solid tumors; Standard of care; T cells; Tumor microenvironment; Tumor proteins; Tumors; Vaccines; Wnt protein; biliary tract cancer; immune checkpoint inhibition; immune microenvironment; gallbladder adenocarcinoma; immunotherapy; perioperative immunotherapy; combination therapy; cholangiocarcinoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15133312

Biliary tract cancers (BTCs), comprising intrahepatic, perihilar, and distal cholangiocarcinoma as well as gallbladder adenocarcinoma, continue to be challenging to manage. Conventional chemotherapy regimens for advanced disease are limited in both options and benefits, and more effective perioperative regimens are also needed. Over the last decade, immunotherapy has had a profound impact on the management of many solid tumor types, particularly in using immune checkpoint inhibition to enable a tumor-directed T cell response. Immunotherapy administered on its own has had limited utility in BTCs, in part due to a hostile immune microenvironment and the relative infrequency of biomarker-based tumor-agnostic indications for immunotherapy. However, immunotherapy in conjunction with chemotherapy, molecularly targeted therapies, and/or anti-angiogenic therapies has gained traction, supported by evidence that these agents can impart favorable immunomodulatory effects on the tumor microenvironment. The TOPAZ-1 trial led to the first BTC-specific immunotherapy approval, establishing the combination of durvalumab with gemcitabine and cisplatin as the preferred first-line treatment for advanced or metastatic disease. Recently, the KEYNOTE-966 trial showed positive results for the combination of pembrolizumab with gemcitabine and cisplatin in the same setting, adding further evidence for the addition of immune checkpoint inhibition to the standard chemotherapy backbone. Meanwhile, advances in the molecular profiling of BTCs has contributed to the recent proliferation of molecularly targeted therapeutics for the subset of BTCs harboring alterations in , , MAP kinase signaling, , and beyond, and there has been great interest in investigating combinations of these agents with immunotherapy. Emerging immunotherapy strategies beyond immune checkpoint inhibition are also being studied in BTCs, and these include immunostimulatory receptor agonists, Wnt signaling modulators, adoptive cell therapy, and cancer vaccines. A large number of trials are underway to explore promising new combinations and immune-targeted strategies, offering opportunities to expand the role of immunotherapy in BTC management in the near future.